Site map
An overview of the available content on this site. Keep the pointer still over an item for a few seconds to get its description.
- Site Set-Up
- FAQ's
- Training
- Documents
- Site Set-Up Training
- Investigator Site File Download (Zip)
- IMP
- Substantial Amendment 1
- Substantial Amendment 2
- Substantial Amendment 3
- Substantial Amendment 4
- Substantial Amendment 5
- PANORAMIC CMDU Resources
- Substantial Amendment 6
- Substantial Amendment 7
- Substantial Amendment 8
- Substantial Amendment 9
- SUBSTANTIAL AMENDMENT 10
- SUBSTANTIAL AMENDMENT 11
- Newsletters 2023
- Substantial Amendment 12
- Recruitment begins for national community COVID-19 antiviral trial
- BBC: Hundreds in Wales take antiviral tablets
- The Guardian: How antivirals provide hope to vulnerable COVID-19 patients
- New study suggests antiviral treatment course is not long enough to treat COVID-19 in at risk patients
- New Scientist: UK has begun using drugs for covid-19 cases before they become severe
- BBC Inside Health (Radio 4): PANORAMIC and anti-virals featured
- BBC: Patients wanted for Oxford and Southampton Unis' take-at-home pill trial
- Over ten thousand participants enrol in world’s largest COVID-19 antiviral study
- University of Bolton student champions praised for support in University of Oxford Covid-19 treatment trials
- Covid 19: Anti-viral drug study open to patients in NI
- Largest Hindu temple in Europe helps to spread awareness of the PANORAMIC study
- PANORAMIC hits the 20,000 participant milestone
- British Muslim organisations support PANORAMIC ahead of Ramadan
- New antiviral, Paxlovid, added to PANORAMIC study
- PANORAMIC trial finds molnupiravir does not reduce COVID-19 hospitalisation/deaths in vaccinated people at high risk
- Professor Chris Butler addresses the UN on PANORAMIC - BAPS UK & Europe collaboration
- Time of India: Places of worship have huge impact on scientific studies
- Reflecting on PANORAMIC and PRINCIPLE, three years into the COVID-19 Pandemic
- Testing Positive for COVID-19?
- PANORAMIC trial finds molnupiravir may not be a cost-effective treatment for COVID-19 in at-risk adults
- PANORAMIC Trial Learnings
- Celebrating innovation: the PRINCIPLE-PANORAMIC Celebratory Symposium
- PRINCIPLE and PANORAMIC teams honoured with prestigious Prix Galien Award